PMID- 7778534
OWN - NLM
STAT- MEDLINE
DCOM- 19950713
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 75
IP  - 18
DP  - 1995 Jun 16
TI  - Safety and efficacy study of delapril versus enalapril in patients with 
      congestive heart failure.
PG  - 44F-49F
AB  - The results after the first 6 months of the 1-year treatment of this multicenter, 
      randomized, open, parallel-group design study of delapril versus enalapril in 
      patients with congestive heart failure (CHF), New York Heart Association (NYHA) 
      classes II and III, are presented. The initial dose of delapril (7.5 mg twice 
      daily) and enalapril (2.5 mg twice daily) could be doubled on a 2-weekly basis 
      (from the beginning of the study) to a maximum of 30 mg twice daily and 10 mg 
      twice daily, respectively. The evaluation of the efficacy was based on the 
      changes of NYHA class, results of exercise testing involving bicycle ergometry 
      (duration of exercise, workload, work performed, double product) performed before 
      and after 3 months' treatment, echocardiography (left ventricular end-diastolic 
      volume and end-systolic volume, ejection fraction, and left ventricular wall 
      stress) at baseline and after 3 and 6 months of treatment and changes in 
      cardiothoracic ratio, electrocardiography, and NYHA class, and patient's opinion 
      of efficacy. Safety was evaluated by monitoring the adverse reactions, laboratory 
      tests, and blood pressure. At 3 months, both treatments had produced a 
      significant improvement compared with baseline in the duration of exercise, 
      workload, and work performed in the bicycle ergometry test as well as in the 
      ejection fraction and in left ventricular wall stress after 6 months of 
      treatment. In addition, after 3 and 6 months of treatment, delapril produced a 
      significant decrease in left ventricular end-systolic volume. Improvement of at 
      least one NYHA class was observed in 20% of delapril patients and 14% of 
      enalapril patients.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Dalla-Volta, S
AU  - Dalla-Volta S
AD  - Department of Internal Medicine, University of Padua Medical School, Italy.
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Indans)
RN  - 69PN84IO1A (Enalapril)
RN  - W77UAL9THI (delapril)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use
MH  - Blood Pressure/drug effects
MH  - Echocardiography/drug effects
MH  - Enalapril/adverse effects/*therapeutic use
MH  - Exercise Test/drug effects
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Indans/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 1995/06/16 00:00
MHDA- 1995/06/16 00:01
CRDT- 1995/06/16 00:00
PHST- 1995/06/16 00:00 [pubmed]
PHST- 1995/06/16 00:01 [medline]
PHST- 1995/06/16 00:00 [entrez]
AID - S0002-9149(99)80514-1 [pii]
AID - 10.1016/s0002-9149(99)80514-1 [doi]
PST - ppublish
SO  - Am J Cardiol. 1995 Jun 16;75(18):44F-49F. doi: 10.1016/s0002-9149(99)80514-1.